

Aaron Mansfield

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6933252/publications.pdf>

Version: 2024-02-01

187
papers

11,655
citations

66234

42
h-index

32761

100
g-index

193
all docs

193
docs citations

193
times ranked

17071
citing authors

#	ARTICLE	IF	CITATIONS
1	A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma. <i>Investigational New Drugs</i> , 2022, 40, 134-141.	1.2	21
2	Synergistic combination of cytotoxic chemotherapy and cyclinâ€dependent kinase 4/6 inhibitors in biliary tract cancers. <i>Hepatology</i> , 2022, 75, 43-58.	3.6	6
3	Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma. <i>Cancer Research</i> , 2022, 82, 307-319.	0.4	8
4	FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations. <i>Digestive Diseases and Sciences</i> , 2022, 67, 3797-3805.	1.1	4
5	Checkpoint Blockade in Unresectable Pleural Mesothelioma: Event Horizon for Multimodal Therapy. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, , .	0.4	1
6	New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options. <i>Journal of Clinical Oncology</i> , 2022, 40, 681-692.	0.8	26
7	First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. <i>Annals of Oncology</i> , 2022, 33, 488-499.	0.6	99
8	Correlation of Somatostatin Receptor 2 Expression, 68Ga-DOTATATE PET Scan and Octreotide Treatment in Thymic Epithelial Tumors. <i>Frontiers in Oncology</i> , 2022, 12, 823667.	1.3	7
9	Lower Exome Sequencing Coverage of Ancestrally African Patients in The Cancer Genome Atlas. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1192-1199.	3.0	6
10	Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial. <i>Npj Precision Oncology</i> , 2022, 6, 13.	2.3	18
11	The Predictive and Prognostic Nature of Programmed Death-Ligand 1 in Malignant Pleural Mesothelioma: A Systematic Literature Review. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100315.	0.6	6
12	Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or pascalisib in advanced solid tumors: a phase I study. , 2022, 10, e004223.		6
13	First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743. <i>Lung Cancer</i> , 2022, 167, 8-16.	0.9	9
14	NKG7 Is a T-cellâ€Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy. <i>Cancer Immunology Research</i> , 2022, 10, 162-181.	1.6	26
15	Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations. <i>Journal of Thoracic Oncology</i> , 2022, 17, 873-889.	0.5	44
16	Validating chemioimmunotherapy in small-cell lung cancer. <i>Lancet Oncology</i> , The, 2022, 23, 692-693.	5.1	3
17	The Evolving Therapeutic Landscape for Malignant Pleural Mesothelioma. <i>Current Oncology Reports</i> , 2022, 24, 1413-1423.	1.8	1
18	Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy. <i>JCO Precision Oncology</i> , 2022, , .	1.5	11

#	ARTICLE	IF	CITATIONS
19	BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 379-388.	1.9	13
20	Human leukocyte antigen expression in paired primary lung tumors and brain metastases in non-small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 215-219.	2.0	9
21	Utilization Trends and Factors Associated With ROS1 Testing Among Patients With Advanced Non-small-cell Lung Cancer in US Community Practices. <i>Clinical Lung Cancer</i> , 2021, 22, e470-e480.	1.1	10
22	First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2021, 397, 375-386.	6.3	638
23	Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion-positive solid tumors. <i>Journal of Clinical Oncology</i> , 2021, 39, 467-467.	0.8	16
24	Heterogeneity of PD-L1 expression between invasive and lepidic components of lung adenocarcinomas. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2651-2656.	2.0	2
25	Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). <i>Journal of Clinical Oncology</i> , 2021, 39, 619-630.	0.8	317
26	Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups. <i>Npj Precision Oncology</i> , 2021, 5, 22.	2.3	17
27	First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancer. <i>Investigational New Drugs</i> , 2021, 39, 1348-1356.	1.2	22
28	A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3630-3640.	3.2	11
29	Ablative radiotherapy for ultracentral lung cancers: Dosimetric, geometric, and volumetric predictors of outcomes and toxicity. <i>Radiotherapy and Oncology</i> , 2021, 158, 246-252.	0.3	9
30	SATB2 Is Expressed in a Subset of Pulmonary and Thymic Neuroendocrine Tumors. <i>American Journal of Clinical Pathology</i> , 2021, 156, 853-865.	0.4	1
31	Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. <i>Lancet Oncology, The</i> , 2021, 22, 959-969.	5.1	222
32	A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors. <i>Npj Precision Oncology</i> , 2021, 5, 74.	2.3	27
33	Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1-Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100205.	0.6	32
34	Tumor Junction Burden and Antigen Presentation as Predictors of Survival in Mesothelioma Treated With Immune Checkpoint Inhibitors. <i>Journal of Thoracic Oncology</i> , 2021, , .	0.5	11
35	Influence of Sociodemographic Factors on Treatment Decisions in Non-small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, e115-e129.	1.1	19
36	Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2020, 141, 199-208.	1.3	18

#	ARTICLE	IF	CITATIONS
37	Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles. <i>J Clin Invest</i> , 2020, 130, e001113.		32
38	Maintaining Equipose With Maintenance Therapy in Mesothelioma. <i>Clinical Lung Cancer</i> , 2020, 21, 482-484.	1.1	0
39	Optimizing clinical cytology touch preparations for next generation sequencing. <i>Genomics</i> , 2020, 112, 5313-5323.	1.3	4
40	ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance. <i>Oncol Immunology</i> , 2020, 9, 1744980.	2.1	77
41	Delta-Like Protein 3 Expression and Targeting in Merkel Cell Carcinoma. <i>Oncologist</i> , 2020, 25, 810-817.	1.9	11
42	Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. <i>Journal of Clinical Oncology</i> , 2020, 38, 2407-2417.	0.8	102
43	Osimertinib-Induced Cardiomyopathy. <i>JACC: Case Reports</i> , 2020, 2, 641-645.	0.3	15
44	Correlation of novel ALK ATI with ALK immunohistochemistry and clinical outcomes in metastatic melanoma. <i>Histopathology</i> , 2020, 77, 601-610.	1.6	5
45	Impact of delaying initiation of anaplastic lymphoma kinase inhibitor treatment on survival in patients with advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2020, 143, 86-92.	0.9	14
46	Chromosomal rearrangements and their neoantigenic potential in mesothelioma. <i>Translational Lung Cancer Research</i> , 2020, 9, S92-S99.	1.3	23
47	Integrating genomic features for non-invasive early lung cancer detection. <i>Nature</i> , 2020, 580, 245-251.	13.7	379
48	Detection of Nonreciprocal/Reciprocal ALK Translocation as Poor Predictive Marker in Patients With First-Line Crizotinib-Treated ALK-Rearranged NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1027-1036.	0.5	55
49	Tumor Mutational Burden From Tumor-Only Sequencing Compared With Germline Subtraction From Paired Tumor and Normal Specimens. <i>JAMA Network Open</i> , 2020, 3, e200202.	2.8	40
50	Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population. <i>Lung Cancer</i> , 2020, 141, 82-88.	0.9	23
51	Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial. <i>Annals of Oncology</i> , 2020, 31, 310-317.	0.6	105
52	Targeting the Cardiotoxicity of Epidermal Growth Factor Receptor Inhibitors. <i>JACC: CardioOncology</i> , 2020, 2, 11-12.	1.7	3
53	Surgery for Mesothelioma After Radiation Therapy (SMART); A Single Institution Experience. <i>Frontiers in Oncology</i> , 2020, 10, 392.	1.3	0
54	HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer. <i>Oncol Immunology</i> , 2020, 9, 1744947.	2.1	26

#	ARTICLE	IF	CITATIONS
55	A Population-based Study of Immunotherapy-related Toxicities in Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, 421-427.e2.	1.1	30
56	Detecting and Filtering Immune-Related Adverse Events Signal Based on Text Mining and Observational Health Data Sciences and Informatics Common Data Model: Framework Development Study. <i>JMIR Medical Informatics</i> , 2020, 8, e17353.	1.3	6
57	Abstract A120: Sex differences in tolerability and response to immune checkpoint inhibitors in non-small cell lung cancer patients. , 2020, , .		0
58	Incidence of major hemorrhage after aggressive image-guided liver mass biopsy in the era of individualized medicine. <i>Abdominal Radiology</i> , 2019, 44, 2067-2073.	1.0	12
59	Pathologic Considerations and Standardization in Mesothelioma Clinical Trials. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1704-1717.	0.5	8
60	Current Diagnosis and Management of Small-Cell Lung Cancer. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1599-1622.	1.4	175
61	Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 402-429.	157.7	306
62	Using Genomics to Differentiate Multiple Primaries From Metastatic Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1567-1582.	0.5	55
63	Expression of delta-like protein 3 is reproducibly present in a subset of small cell lung carcinomas and pulmonary carcinoid tumors. <i>Lung Cancer</i> , 2019, 135, 73-79.	0.9	16
64	An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-“Small-Cell Lung Cancer. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-15.	1.0	81
65	Nivo-lution in Mesothelioma. <i>Clinical Cancer Research</i> , 2019, 25, 5438-5440.	3.2	7
66	Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee “ International Association for the Study of Lung Cancer “ Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1718-1731.	0.5	15
67	Loss of ATRX expression predicts worse prognosis in pulmonary carcinoid tumors. <i>Human Pathology</i> , 2019, 94, 78-85.	1.1	5
68	Immune Cell Infiltration May Be a Key Determinant of Long-Term Survival in Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1286-1295.	0.5	75
69	Understanding heterogeneous tumor microenvironment in metastatic melanoma. <i>PLoS ONE</i> , 2019, 14, e0216485.	1.1	36
70	Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?. <i>Oncologist</i> , 2019, 24, e1148-e1155.	1.9	81
71	Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials. <i>Oncologist</i> , 2019, 24, 96-102.	1.9	35
72	Heterogeneity of programmed death-“ligand 1 expression in thymic epithelial tumours between initial specimen and synchronous or metachronous metastases or recurrences. <i>Histopathology</i> , 2019, 74, 364-367.	1.6	6

#	ARTICLE	IF	CITATIONS
73	Identification and Development of a Lung Adenocarcinoma PDX Model With STRN-ALK Fusion. <i>Clinical Lung Cancer</i> , 2019, 20, e142-e147.	1.1	11
74	Prospective Immunophenotyping of CD8+ T Cells and Associated Clinical Outcomes of Patients With Oligometastatic Prostate Cancer Treated With Metastasis-Directed SBRT. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 229-240.	0.4	24
75	Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2019, 14, 276-287.	0.5	92
76	Predicting Treatment Response Based on RNA Expression in Large Datasets. <i>Clinical Cancer Research</i> , 2019, 25, 1443-1445.	3.2	1
77	A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors. <i>Investigational New Drugs</i> , 2019, 37, 684-692.	1.2	30
78	Understanding Clinical Trials in Malignant Mesothelioma. , 2019, , 187-202.		0
79	Contraction of T cell richness in lung cancer brain metastases. <i>Scientific Reports</i> , 2018, 8, 2171.	1.6	74
80	Detection and localization of surgically resectable cancers with a multi-analyte blood test. <i>Science</i> , 2018, 359, 926-930.	6.0	1,872
81	Nomogram prediction of overall survival for patients with non-small-cell lung cancer incorporating pretreatment peripheral blood markers. <i>European Journal of Cardio-thoracic Surgery</i> , 2018, 53, 1214-1222.	0.6	23
82	Significance of Immune Checkpoints in Lung Cancer. , 2018, , 59-77.		0
83	Progress in the Management of Malignant Pleural Mesothelioma in 2017. <i>Journal of Thoracic Oncology</i> , 2018, 13, 606-623.	0.5	67
84	Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years. <i>Journal of Oncology Practice</i> , 2018, 14, e1-e10.	2.5	245
85	Identification, Prioritization, and Treatment of Mutations Identified by Next-Generation Sequencing. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 873-880.	1.8	6
86	Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy. <i>Heliyon</i> , 2018, 4, e01039.	1.4	37
87	First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 2220-2229.	13.9	2,228
88	Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1655-1667.	0.5	85
89	Multifocal Pulmonary Adenocarcinoma with Ground-Glass/Lepidic Features – Exciting Times as the Mystery Is Unfolding. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1616-1618.	0.5	1
90	9. Detection of fusion genes from complex rearrangements reported by genome-wide mate-pair sequencing (MPseq). <i>Cancer Genetics</i> , 2018, 224-225, 53-54.	0.2	0

#	ARTICLE	IF	CITATIONS
91	Effects of Reduction in Tumor Burden on Survival in Epithelioid Malignant Pleural Mesothelioma. Mayo Clinic Proceedings, 2018, 93, 1026-1033.	1.4	6
92	DARPP-32 and t-DARPP promote non-small cell lung cancer growth through regulation of IKK1±-dependent cell migration. Communications Biology, 2018, 1, 43.	2.0	25
93	Comparison of Risk Stratification Models to Predict Recurrence and Survival in Pleuropulmonary Solitary Fibrous Tumor. Journal of Thoracic Oncology, 2018, 13, 1349-1362.	0.5	38
94	CX3CR1 identifies PD-1 therapyâ€“responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. JCI Insight, 2018, 3, .	2.3	106
95	Is durvalumab the solution for unresectable stage III non-small cell lung cancer?. Translational Cancer Research, 2018, 7, S89-S93.	0.4	0
96	Immune checkpoint inhibition in malignant mesothelioma: Does it have a future?. Lung Cancer, 2017, 105, 49-51.	0.9	8
97	Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial. Clinical Cancer Research, 2017, 23, 3277-3284.	3.2	82
98	Meta-analysis on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer. Thrombosis Research, 2017, 154, 28-34.	0.8	36
99	Towards a Molecular Classification of Pulmonary Sarcomatoid Carcinomas. Journal of Thoracic Oncology, 2017, 12, 910-912.	0.5	3
100	Treating Philadelphia chromosome/ <i>BCR-ABL1</i> positive patients with Glivec (Imatinib mesylate): 10Âyearsâ€™ experience at Patan Hospital, Nepal. British Journal of Haematology, 2017, 177, 991-999.	1.2	3
101	OA13.07 Intrapleural Modified Vaccine Strain Measles Virus Therapy for Patients with Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2017, 12, S296.	0.5	10
102	A proof-of-concept trial of protein kinase C iota inhibition with auranofin for the paclitaxel-induced acute pain syndrome. Supportive Care in Cancer, 2017, 25, 833-838.	1.0	7
103	Predictors of relapse and evaluation of the role of postoperative radiation therapy in a modern series of patients with surgically resected stage III (N2) nonâ€“small cell lung cancer. Advances in Radiation Oncology, 2017, 2, 12-18.	0.6	1
104	Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer: reply. Journal of Thrombosis and Haemostasis, 2017, 15, 591-592.	1.9	2
105	Feasibility and Acceptability of a Dignity Therapy/Life Plan Intervention for Patients With Advanced Cancer. Oncology Nursing Forum, 2017, 44, E194-E202.	0.5	12
106	Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992â€“2011. Cancer Medicine, 2017, 6, 2203-2212.	1.3	98
107	Local and systemic immunity predict survival in patients with pulmonary sarcomatoid carcinoma. Medical Oncology, 2017, 34, 140.	1.2	1
108	FDG-PET parameters as predictors of pathologic response and nodal clearance in patients with stage III non-small cell lung cancer receiving neoadjuvant chemoradiation and surgery. Practical Radiation Oncology, 2017, 7, e531-e541.	1.1	9

#	ARTICLE	IF	CITATIONS
109	Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma. <i>Oncolimmunology</i> , 2017, 6, e1356146.	2.1	27
110	Pulmonary sarcomatoid carcinoma—a new hope. <i>Annals of Oncology</i> , 2017, 28, 1417-1418.	0.6	17
111	Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery. <i>Oncotarget</i> , 2017, 8, 27145-27154.	0.8	55
112	Molecular Modeling and Functional Analysis of Exome Sequencing—Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma. <i>JCO Precision Oncology</i> , 2017, 2017, 1-13.	1.5	4
113	Predictors of active cancer thromboembolic outcomes: role of body composition. <i>International Angiology</i> , 2017, 36, 88-89.	0.4	1
114	Management of Multifocal Lung Cancer: Results of a Survey. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1398-1402.	0.5	27
115	Bim and soluble PD-L1 (sPD-L1) as predictive biomarkers of response to anti-PD-1 therapy in patients with melanoma and lung carcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11534-11534.	0.8	12
116	Checkmate 743: A phase 3, randomized, open-label trial of nivolumab (nivo) plus ipilimumab (ipi) vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS8581-TPS8581.	0.8	14
117	ATOMIC-Meso: A randomized phase 2/3 trial of ADI-PEG20 or placebo with pemetrexed and cisplatin in patients with argininosuccinate synthetase 1-deficient non-epithelioid mesothelioma.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS8582-TPS8582.	0.8	7
118	EGFR mediates activation of RET in lung adenocarcinoma with neuroendocrine differentiation characterized by ASCL1 expression. <i>Oncotarget</i> , 2017, 8, 27155-27165.	0.8	11
119	T cell Bim levels reflect responses to anti-PD-1 cancer therapy. <i>JCI Insight</i> , 2016, 1, .	2.3	68
120	Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1773-1778.	1.9	113
121	Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non-Small Cell Lung Cancer to Receive Immunotherapy. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 220-222.	2.3	22
122	The Effect of Hepatic Impairment on Outcomes in Phase I Clinical Trials in Cancer Subjects. <i>Clinical Cancer Research</i> , 2016, 22, 5472-5479.	3.2	23
123	S768I Mutation in EGFR in Patients with Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1798-1801.	0.5	50
124	c-Met expression and MET amplification in malignant pleural mesothelioma. <i>Annals of Diagnostic Pathology</i> , 2016, 23, 1-7.	0.6	14
125	Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. <i>Annals of Oncology</i> , 2016, 27, 1953-1958.	0.6	289
126	B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8+ T cells. <i>Scientific Reports</i> , 2016, 6, 36722.	1.6	36

#	ARTICLE	IF	CITATIONS
127	Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab. <i>BioDrugs</i> , 2016, 30, 397-405.	2.2	36
128	BCL-2-interacting mediator of cell death (Bim) is a novel biomarker for response to anti-PD-1 therapy in patients with advanced melanoma. <i>Immunotherapy</i> , 2016, 8, 1351-1353.	1.0	6
129	Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib. <i>Annals of Oncology</i> , 2016, 27, 2111-2117.	0.6	57
130	88P: Use of brain imaging in the management of patients with lymph node negative multifocal lung cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, S93-S94.	0.5	2
131	Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2177-2182.	3.2	119
132	Rapidly Appearing Sclerotic Vertebral Lesions in a Patient With an Infiltrative Mediastinal Mass. <i>JAMA Oncology</i> , 2016, 2, 267.	3.4	0
133	CpG-induced antitumor immunity requires IL-12 in expansion of effector cells and down-regulation of PD-1. <i>Oncotarget</i> , 2016, 7, 70223-70231.	0.8	33
134	Severe hepatic dysfunction is associated with venous thromboembolic events in phase 1 clinical trials. <i>Thrombosis Research</i> , 2015, 136, 1169-1173.	0.8	2
135	Nomograms Predict Overall Survival for Patients with Small-Cell Lung Cancer Incorporating Pretreatment Peripheral Blood Markers. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1213-1220.	0.5	122
136	Development and External Validation of a Prognostic Nomogram for Metastatic Uveal Melanoma. <i>PLoS ONE</i> , 2015, 10, e0120181.	1.1	33
137	PD-1 Restrains Radiotherapy-Induced Abscopal Effect. <i>Cancer Immunology Research</i> , 2015, 3, 610-619.	1.6	327
138	DNA methylation and RNA expression profiles in lung adenocarcinomas of never-smokers. <i>Cancer Genetics</i> , 2015, 208, 253-260.	0.2	14
139	Primary venous thromboembolism prophylaxis in patients with solid tumors. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 258-259.	1.0	0
140	Radiotherapy for extensive stage small-cell lung cancer. <i>Lancet, The</i> , 2015, 385, 1291.	6.3	2
141	The Mayo Clinic experience with the use of kinase inhibitors, ipilimumab, bevacizumab, and local therapies in the treatment of metastatic uveal melanoma. <i>Melanoma Research</i> , 2015, 25, 59-63.	0.6	38
142	Evidence of Th2 polarization of the sentinel lymph node (SLN) in melanoma. <i>Oncolmmunology</i> , 2015, 4, e1026504.	2.1	25
143	Spontaneous Regression of Malignant Pleural Mesothelioma in a Patient with New-Onset Inflammatory Arthropathy. <i>Annals of the American Thoracic Society</i> , 2015, 12, 1416-1417.	1.5	6
144	Prospective evaluation of protein C and factor VIII in prediction of cancer-associated thrombosis. <i>Thrombosis Research</i> , 2015, 136, 1120-1125.	0.8	16

#	ARTICLE	IF	CITATIONS
145	Synergy of cancer immunotherapy and radiotherapy. <i>Aging</i> , 2015, 7, 144-145.	1.4	9
146	Skin Cancer Surveillance and Malignancies of the Skin in a Community-Dwelling Cohort of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia. <i>Journal of Oncology Practice</i> , 2014, 10, e1-e4.	2.5	19
147	Concurrent MCL1 and JUN amplification in pseudomyxoma peritonei: a comprehensive genetic profiling and survival analysis. <i>Journal of Human Genetics</i> , 2014, 59, 124-128.	1.1	31
148	Early venous thromboembolic events are associated with worse prognosis in patients with lung cancer. <i>Lung Cancer</i> , 2014, 86, 358-362.	0.9	40
149	Pregnancy-associated plasma protein-A expression in human breast cancer. <i>Growth Hormone and IGF Research</i> , 2014, 24, 264-267.	0.5	31
150	B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1036-1040.	0.5	208
151	Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials. <i>Lung Cancer</i> , 2014, 86, 133-136.	0.9	45
152	Effect of β -Adrenergic Blockers and Other Antihypertensive Drugs on the Risk of Melanoma Recurrence and Death. <i>Mayo Clinic Proceedings</i> , 2014, 89, 1164-1165.	1.4	7
153	Primary venous thromboembolism prophylaxis in patients with solid tumors: a meta-analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 38, 241-249.	1.0	26
154	Immune cell quantitation in normal breast tissue lobules with and without lobulitis. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 539-549.	1.1	65
155	A Predictive Tool to Estimate the Risk of Axillary Metastases in Breast Cancer Patients with Negative Axillary Ultrasound. <i>Annals of Surgical Oncology</i> , 2014, 21, 2229-2236.	0.7	18
156	A phase 1 study of a novel inhibitor of protein phosphatase 2A alone and with docetaxel. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS2636-TPS2636.	0.8	3
157	A novel method for identifying downstream signals in tumor-reactive T cells following PD-1 engagement and monitoring endogenous tumor immunity and immunotherapy. <i>Journal of Clinical Oncology</i> , 2014, 32, 3049-3049.	0.8	0
158	The Mayo Clinic experience with the use of kinase inhibitors (KIs), ipilimumab, and bevacizumab in the treatment of metastatic ocular melanoma. <i>Journal of Clinical Oncology</i> , 2014, 32, e20011-e20011.	0.8	0
159	Association of early venous thromboembolic events with worse prognosis in patients with lung cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, e20623-e20623.	0.8	0
160	Reflections on immune checkpoint inhibition in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2014, 3, 411-3.	1.3	9
161	The Role of Vascular Endothelial Growth Factor in the Pathogenesis, Diagnosis and Treatment of Malignant Pleural Effusion. <i>Current Oncology Reports</i> , 2013, 15, 207-216.	1.8	61
162	Up-regulation of pro-angiogenic factors and establishment of tolerance in malignant pleural effusions. <i>Lung Cancer</i> , 2013, 82, 63-68.	0.9	12

#	ARTICLE	IF	CITATIONS
163	Comparison of Fluorescence In Situ Hybridization (FISH) and Dual-ISH (DISH) in the Determination of HER2 Status in Breast Cancer. <i>American Journal of Clinical Pathology</i> , 2013, 139, 144-150.	0.4	33
164	Inhibition of Angiogenesis for the Treatment of Metastatic Melanoma. <i>Current Oncology Reports</i> , 2013, 15, 492-499.	1.8	5
165	Phase I dose escalation study of the PKC δ inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer. <i>Anti-Cancer Drugs</i> , 2013, 24, 1079-1083.	0.7	47
166	The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma. <i>Oncolmmunology</i> , 2013, 2, e24436.	2.1	37
167	Asphyxiation with a Fentanyl Patch. <i>Case Reports in Oncology</i> , 2013, 6, 242-244.	0.3	27
168	Predictors Of Cancer Associated Thrombosis. <i>Blood</i> , 2013, 122, 3616-3616.	0.6	93
169	Regional lymphatic immunity in melanoma. <i>Melanoma Research</i> , 2012, 22, 9-18.	0.6	18
170	Normal ageing is associated with an increase in Th2 cells, MCP-1 (CCL1) and RANTES (CCL5), with differences in sCD40L and PDGF-AA between sexes. <i>Clinical and Experimental Immunology</i> , 2012, 170, 186-193.	1.1	70
171	The presence of sinusoidal CD163+ macrophages in lymph nodes is associated with favorable nodal status in patients with breast cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012, 461, 639-646.	1.4	14
172	68-Year-Old Man With Neutropenic Fever and Upper Extremity Hematoma. <i>Mayo Clinic Proceedings</i> , 2012, 87, 1226-1229.	1.4	1
173	An organ system-based approach to prognosis in advanced melanoma. <i>Frontiers in Bioscience - Elite</i> , 2012, E4, 2723-2733.	0.9	8
174	Regional immunity in melanoma: immunosuppressive changes precede nodal metastasis. <i>Modern Pathology</i> , 2011, 24, 487-494.	2.9	51
175	Metastasis to sentinel lymph nodes in breast cancer is associated with maturation arrest of dendritic cells and poor co-localization of dendritic cells and CD8+ T cells. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011, 459, 391-398.	1.4	41
176	The dynamic human immune response to cancer: it might just be rocket science. <i>Immunotherapy</i> , 2011, 3, 1021-1024.	1.0	7
177	Resectable pancreatic small cell carcinoma. <i>Rare Tumors</i> , 2011, 3, 13-17.	0.3	18
178	No Association of BRCA Mutations with Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in Patients Treated for Breast or Ovarian Cancer. <i>Blood</i> , 2011, 118, 4259-4259.	0.6	1
179	Hydroxycarbamide-induced dermatopathy. <i>American Journal of Hematology</i> , 2010, 85, 75-76.	2.0	3
180	Mayo Clinic Experience With Very Rare Exocrine Pancreatic Neoplasms. <i>Pancreas</i> , 2010, 39, 972-975.	0.5	23

#	ARTICLE	IF	CITATIONS
181	Patan hospital experience in treating philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukemia patients with gleevec (imatinib mesylate); the first generation specific tyrosine kinase inhibitor. BMC Hematology, 2010, 10, 8.	2.6	3
182	Angiomatoid fibrous histiocytoma in a 25-year-old male. Rare Tumors, 2010, 2, 54-56.	0.3	16
183	Novel therapeutics for the treatment of metastatic melanoma. Future Oncology, 2009, 5, 543-557.	1.1	20
184	Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer. BMC Cancer, 2009, 9, 231.	1.1	91
185	71-Year-Old Man With Chronic Kidney Failure and Sudden Change of Mental Status. Mayo Clinic Proceedings, 2009, 84, e5-e8.	1.4	4
186	Trials, tribunals, and opportunities for lung cancer KRASG12C brain metastases. Clinical Cancer Research, 0, , .	3.2	0
187	Response to Mittr and Pollack. Journal of the National Cancer Institute, 0, , .	3.0	0